Keryx Biopharmaceuticals: This Analyst Blames Slowing Script Growth for Bad Q3 Outcome

Keryx Biopharmaceuticals (NASDAQ:KERX) has commercial adoption challenges ahead for its iron deficiency anemia asset Auryxia, says Cowen analyst Boris Peaker. After the company’s drug came up short of the Street to the tune of a $3.6 million miss, slowing prescription growth does not fire up confidence for shareholders.

Story Continues

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts